GlassScriptPhysician profile
Tara Baird
NPI 1124495049
$4,857.74
in general payments reported to CMS, 2019-2025
20 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $852 · 2022: $479 · 2023: $1,223 · 2024: $1,107 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,527.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,205.24 | 2021-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,022.19 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $517.80 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $431.44 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $380.98 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $296.16 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $149.11 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $121.49 | 2021-2024 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $119.82 | 2022-2025 | Uzedy, Austedo Xr |
| Indivior INC. | $113.90 | 2022-2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $109.06 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $96.31 | 2025 | Cobenfy |
| Lundbeck LLC | $83.55 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $58.71 | 2021-2022 | |
| Eisai INC. | $31.23 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.79 | 2021-2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $27.31 | 2023-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $26.87 | 2021 | |
| Biogen, INC. | $20.89 | 2024 | |
| Corium, LLC | $17.89 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Baird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.